Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2021-12-02 00:00:00 ET · period of report 2021-11-30 · accession 0001209191-21-067613 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-02 | 2021-11-30 | ABOS | OConnell Daniel Joseph | Pres, CEO, Dir | M - OptEx | $4.47 | +1,118 | 2,685 | +71% | +$4,997 |
| D | 2021-12-02 | 2021-11-30 | ABOS | OConnell Daniel Joseph | Pres, CEO, Dir | M - OptEx | $0.00 | -1,118 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-30 | M | A | 1,118 | $4.47 | 2,685 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-11-30 | M | D | 1,118 | $0.00 | 0 | D | $4.47 · — to 2021-12-01 | 1,118 Common Stock | (F1) Immediately exercisable. |